Basic Information
| LncRNA/CircRNA Name | LINP1 |
| Synonyms | lncRNA in nonhomologous end joining pathway 1 |
| Region | GRCh38_10:6737382-6739026 |
| Ensemble | ENSG00000223784 |
| Refseq | NR_138480 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | apoptosis | Drug | Tamoxifen | |
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | breast cancer |
| ICD-0-3 | C50 |
| Methods | Microarray, qRT-PCR, Western blot assay |
| Sample | breast cancer cells MCF-7 and T47D |
| Expression Pattern | up-regulated |
| Function Description | the expression of lncRNA in nonhomologous end joining pathway 1 (LINP1) was increased in tamoxifen-resistant breast cancer cells, and that LINP1 knockdown significantly attenuated the tamoxifen resistance and viability of tamoxifen-resistant breast cancer cells in vitro and in vivo. LINP1 knockdown increased apoptosis in cells following treatment with tamoxifen. Furthermore, LINP1 overexpression resulted in increased cell mobility by regulating the EMT process. Mechanistically, LINP1 is a direct target of ER-mediated transcriptional repression, and both tamoxifen treatment and hormone deprivation increased the expression of LINP1. LINP1 overexpression was associated with downregulation of the levels of ER protein and attenuated the estrogen response. |
| Pubmed ID | 31927036 |
| Year | 2020 |
| Title | LncRNA LINP1 Confers Tamoxifen Resistance and Negatively Regulated by ER Signaling in Breast Cancer |
External Links
| Links for LINP1 | GenBank HGNC NONCODE |
| Links for breast cancer | OMIM COSMIC |